Haemonetics Corp (HAE) · Aug 6, 2026 · Company update

Revenue and adjusted EPS beat estimates; full-year growth outlook moved higher

Revenue and adjusted EPS beat estimates; full-year growth outlook moved higher

The quarter came in ahead of the standing estimate. Published expectations were roughly $331 million of revenue and $1.08–$1.09 of adjusted EPS; Haemonetics delivered $339.4 million and $1.14, or about 2.5% and 5% above those benchmarks, respectively.

MetricQ1 FY27Q1 FY26Change / expectation
Revenue$339.4M$321.4M+5.6%; above published consensus of roughly $331M
Organic revenue growth5.9%—Above prior company guidance range of 3–6%
Adjusted EPS$1.14$1.10+3.6%; above published consensus of roughly $1.08–$1.09
Reported EPS$0.72$0.70+2.9%
Adjusted operating margin23.4%24.1%Down 70 basis points
Operating cash flow$52.3M$17.4MUp $34.9M
Free cash flow$39.1M$2.5MUp $36.6M

Growth was broad enough to support the beat. Plasma grew organically 8.2% and Blood Management Technologies 8.1%, while Interventional Technologies returned to 2.8% organic growth; total organic revenue growth was 5.9% (Revenue Analysis by Business Unit). That is stronger than the prior full-year organic-growth framework and reduces concern that the recovery depends on only one business.

The earnings quality was less clean than the headline suggests. Adjusted operating income fell 2.2% and adjusted operating margin contracted to 23.4% as personnel and freight costs rose (Adjusted Measures Reconciliation). Reported net income declined 3.0% to $33.0 million because the tax rate rose to 30.6%, while higher interest expense also weighed on earnings (Income Statement). In other words, the EPS beat came alongside limited underlying operating leverage rather than accelerating margins.

The most important incremental positive was the guidance increase. Full-year reported revenue guidance rose from 4–7% growth to 5–8%, and organic-growth guidance increased from 3–6% to 4–7%; adjusted-margin expansion and roughly 80% free-cash-flow conversion were maintained (Total Company Guidance). That is a genuine improvement versus what had been assumed, although the unchanged margin target means management is raising the growth outlook without raising its profitability ambition.

Cash generation improved sharply, but the quarter benefited from timing. Operating cash flow and free cash flow surged, primarily because of favorable receivables collections and lower equipment transfers rather than a comparable increase in net income (Cash Flow statement). The company also repaid $51.6 million of borrowings, leaving cash at $223.4 million (Balance Sheet; Cash Flow statement). Net, the estimate beat plus higher revenue outlook outweigh the margin pressure, producing a moderate positive read.

Original filing on SEC EDGAR

More Haemonetics Corp news

Revenue and adjusted EPS beat estimates; full-year growth outlook moved higher | HAE Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.